1. [New directions in biomarker research, drug development and personalized medicine].
- Author
-
Németh G and Jelinek I
- Subjects
- Biomarkers, Tumor, Chronic Disease drug therapy, Evidence-Based Medicine, Humans, Neoplasms diagnosis, Neoplasms drug therapy, Neoplasms genetics, Pathology, Molecular, Pharmacogenetics, Predictive Value of Tests, Prognosis, Reagent Kits, Diagnostic, Biomarkers, Drug Design, Molecular Targeted Therapy trends, Precision Medicine trends
- Abstract
In recent years, medicine has taken some important first steps toward a major paradigm shift that could result in a landslide for personalized therapies. Indeed, evidence-based medicine seems to yield to personalized medicine in multiple areas, including both the thinking patterns of healthcare workers and everyday medical practice. Nevertheless, although a steadily increasing number of personalized treatment modalities have recently become available for patients, so far, no breakthrough can be seen in the paradigm shift from evidence-based medicine to personalized therapy. We believe that a more efficient identification and utilisation of future and already known biomarkers, respectively, might be the key to speed up this progress. In line with this, biomarkers are becoming increasingly important tools in late stage research, drug development and in clinical practice, as well. Correct classification of biomarkers becomes especially important, as different types of biomarkers provide markedly different information to drug developers and health care professionals.
- Published
- 2013
- Full Text
- View/download PDF